Adherence to quality indicators and survival in patients with breast cancer

Medical Care

Volumn 47, Issue 2, 2009, Pages 217-225

  Cheng, Skye H ^a,b   Wang, C Jason ^c,d   Lin, Jin Long ^e,h   Horng, Cheng Fang ^a   Lu, Mei Chun ^a   Asch, Steven M ^c,f,g   Hilborne, Lee H ^c,f   Liu, Mei Ching ^a   Chen, Chii Ming ^a   Huang, Andrew T ^a,b  

^a KOO FOUNDATION SUN YAT SEN CANCER CENTER   (Taiwan)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c RAND CORPORATION   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Bureau of National Health Insurance Taiwan   (Taiwan)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^h Department of Health ^*  (Taiwan)

Author keywords

Adherence; Breast cancer; Quality indicator; Quality of care

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; BREAST CANCER; CALCULATION; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; HAZARD RATIO; HEALTH CARE QUALITY; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHYSICIAN; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; SURVIVAL RATE; UNIVARIATE ANALYSIS; ADULT; AGED; BREAST TUMOR; CANCER STAGING; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PRACTICE GUIDELINE; STANDARD; SURVIVAL; TAIWAN; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; BREAST NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GUIDELINE ADHERENCE; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PROPORTIONAL HAZARDS MODELS; QUALITY INDICATORS, HEALTH CARE; SURVIVAL ANALYSIS; TAIWAN;

EID: 59049093806     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLR.0b013e3181893c4a     Document Type: Article

References (45)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001;37(Suppl 8):S4-S66.
2. Hillner BE, McDonald MK, Penberthy L, et al. Measuring standards of care for early breast cancer in an insured population. J Clin Oncol. 1997;15:1401-1408.
3. Ottevanger PB, De Mulder PH, Grol RP, et al. Adherence to the guidelines of the CCCE in the treatment of node-positive breast cancer patients. Eur J Cancer. 2004;40:198-204.
4. Malin JL, Schuster MA, Kahn KA, et al. Quality of breast cancer care: what do we know? J Clin Oncol. 2002;20:4381-4393.
5. Nattinger AB. Quality of care for breast cancer. Med Care. 2003;41: 341-343.
6. Consensus conference. Adjuvant chemotherapy for breast cancer. JAMA. 1985;254:3461-3463.
7. McGlynn EA, Asch SM, Adams J, et al. The quality of health care delivered to adults in the United States. N Engl J Med. 2003;348:2635-2645.
8. Cancer Trends Progress Report - 2005 Update. Available at: http://progressreport.cancer.gov. National Cancer Institute, NIH, DHHS, Bethesda, MD; 2005.
9. Institute of Medicine Report: Crossing the Quality Chasm: A New Health System for the 21st Century: Committee on Quality Health Care in America, Institute of Medicine. National Academy of Science; 2001.
10. Schuster MA, McGlynn EA, Brook RH. How good is the quality of health care in the United States? Milbank Q. 1998;76:517-563, 509.
11. Wang CJ, McGlynn EA, Brook RH. Quality-of-care indicators for the neuro-developmental follow-up of very-low-birth-weight children: results of an expert panel process. Pediatrics. 2006;117:2080-2092.
12. Schuster MA, Asch SM, McGlynn EA, et al. Development of a quality of care measurement system for children and adolescents. Methodological considerations and comparisons with a system for adult women. Arch Pediatr Adolesc Med. 1997;151:1085-1092.
13. Higashi T, Shekelle PG, Adams JL, et al. Quality of care is associated with survival in vulnerable older patients. Ann Intern Med. 2005;143: 274-281.
14. Moher D, Schachter H, Mamaladze V, et al. Measuring the Quality of Breast Cancer Care in Women. Summary, Evidence Report/Technology Assessment No. 105: Prepared by the University of Ottawa Evidence-based Practice Center under Contract No. 290-02-0021. AHRQ Publication No. 04-E030-1. Rockville, MD: Agency for Healthcare Research and Quality; 2004.
15. Brook RH. The RAND/UCLA Appropriateness Method. In: McCormick KA, Moorse SR, Siegei RA, eds. Clinical Practice Guideline Development: Methodology Perspectives. Rockville, MD: Public Health Service, AHCPR Pub. No. 95-0009; 1994.
16. Malin JL, Asch SM, Kerr EA, et al. Evaluating the quality of cancer care: development of cancer quality indicators for a global quality assessment tool. Cancer. 2000;88:701-707.
17. Cancer Care Outcomes Research & Surveillance Consortium. Available at: http://Healthservices.Cancer.Gov/Cancors/. Accessed February 14, 2006.
18. Cheng SH, Tsou MH, Liu MC, et al. Unique features of breast cancer in Taiwan. Breast Cancer Res Treat. 2000;63:213-223.
19. Nolan T, Berwick DM. AU-or-none measurement raises the bar on performance. JAMA. 2006;295:1168-1170.
20. Shen Y, Yang Y, Inoue LY, et al. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst. 2005;97:1195-1203.
21. Rawal R, Lorenzo Bermejo J, Hemminki K. Risk of subsequent invasive breast carcinoma after in situ breast carcinoma in a population covered by national mammographic screening. Br J Cancer. 2005;92:162-166.
22. Henson DE, Ries L, Freedman LS, et al. Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index. Cancer. 1991;68:2142-2149.
23. Dixon JM, Rodger A, Stebbing J. Breast cancer (non-metastatic). Clin Evid. 2005;13:2226-2257.
24. Somner JE, Dixon JM, Thomas JS. Node retrieval in axillary lymph node dissections: recommendations for minimum numbers to be confident about node negative status. J Clin Pathol. 2004;57:845-848.
25. Taghian A, Jeong JH, Mamounas E, et al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol. 2004;22:4247-4254.
26. Blamey RW. Guidelines on endocrine therapy of breast cancer EU-SOMA. Eur J Cancer. 2002;38:615-634.
27. Vinh-Hung V, Verschraegen C. Breast-conserving surgery with or without radiotherapy: pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality. J Natl Cancer Inst. 2004;96:115-121.
28. Fisher B, Bauer M, Margolese R, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med. 1985;312:665-673.
29. Buchholz TA, Austin-Seymour MM, Moe RE, et al. Effect of delay in radiation in the combined modality treatment of breast cancer. Int J Radiat Oncol Biol Phys. 1993;26:23-35.
30. Whelan TJ. Use of conventional radiation therapy as part of breast-conserving treatment. J Clin Oncol. 2005;23:1718-1725.
31. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 2000;355:1757-1770.
32. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-1717.
33. Colleoni M, Litman HJ, Castiglione-Gertsch M, et al. Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF. Br J Cancer. 2002;86:1705-1714.
34. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457-481.
35. Mantel N, Haenszel W. Chi-square test with one degree of freedom: extensions of the Mantel-Haenszel procedure. J Am Stat Soc. 1963;58: 690-700.
36. Sarle WS. Prediction with Missing Inputs. Cary, NC: SAS Institute Inc, SAS Campus Drive; 1998.
37. Yuan YC. Multiple Imputation for Missing Data: Concepts and New Development. Rockville, MD: SAS Institute Inc; 1998:267-225.
38. Williams SC, Schmaltz SP, Morton DJ, et al. Quality of care in U.S. hospitals as reflected by standardized measures, 2002-2004. N Engl J Med. 2005;353:255-264.
39. Early Breast Cancer Trialists' Collaborative Group. Multi-agent chemotherapy for early breast cancer. Cochrane Database Syst Rev. 2002: CD000487.
40. Asch SM, Kerr EA, Hamilton EG, et al. Quality of Care for Oncologic Conditions and HIV: A Review of the Literature and Quality Indicators. Santa Monica, CA: RAND Health; 2000.
41. Cancer Registry Annual Report, 2002, Republic of China (Taiwan). Taipei: Bureau of Health Promotion, Department of Health; 2005.
42. Li CI, Malone KE, Daling JR. Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomarkers Prev. 2002;11: 601-607.
43. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333:15.
44. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21:976-983.
45. Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005;23: 3686-3696.